| Business Summary | | CYTYC
Corporation
designs,
develops,
manufactures
and
markets
a
sample
preparation
system
for
medical
diagnostic
applications.
The
Company's
ThinPrep
System
allows
for
the
automated
preparation
of
cervical
cell
specimens
on
microscope
slides
for
use
in
cervical
cancer
screening,
as
well
as
for
the
automated
preparation
of
other
cell
specimens
on
microscope
slides
for
use
in
non-gynecological
testing
applications.
The
product
has
been
approved
as
a
replacement
for
the
conventional
Pap
smear
method.
Its
product
labeling
also
includes
the
claim
that
the
ThinPrep
System
is
significantly
more
effective
in
detecting
Low
Grade
Squamous
Intraepithelial
Lesions
(LGSIL)
and
more
severe
lesions
than
the
conventional
Pap
smear
method
in
a
variety
of
patient
populations. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CYTYC
Corporation
designs,
develops,
manufactures
and
markets
a
sample
preparation
system
for
medical
diagnostic
applications.
For
the
six
months
ended
6/30/01,
net
sales
rose
61%
to
$100.5
million.
Net
income
totaled
$31.6
million,
up
from
$12.4
million.
Revenues
reflect
increased
sales
of
the
Company's
ThinPrep
Pap
Test
for
cervical
cancer
screening
in
the
United
States.
Earnings
also
benefited
from
higher
operating
margins
and
$3.1
million
in
litigation
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Monroe Trout, M.D., 70 Chairman | -- | -- | Patrick Sullivan, 49 Vice
Chairman, Pres, CEO | $808K | $6.2M | C. William McDaniel, 60 Vice
Chairman | -- | -- | Robert Bowen, 51 CFO,
VP, Treasurer | -- | -- | Daniel Levangie, 50 COO,
Exec. VP | 479K | 7.6M | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|